Pharmaceuticals News and Research

RSS

Protein transporter in the gut could speed drug 'take up'

For poorly absorbed medications, drug makers should consider using natural homing devices to drive the drugs through the hazards of gastrointestinal acidity and enzymes to reach the bloodstream quicker, James Polli, PhD, said today at the annual meeting of the American Association of Pharmaceutical Scientists (AAPS) in Atlanta.

18 Nov 2008

First simulation of the the ageing process

The first simulation of how it feels to age decades in minutes will be run by staff from Eisai at the new University of Hertfordshire simulation centre tomorrow (19 November).

18 Nov 2008

Gel Technologies raises $9 million

Gel Technologies Ltd today announced the successful completion of an investment round of $9 million.

18 Nov 2008

Maas Biolab scientists validate cyclosporin human neuroprotection

Maas Biolab researchers CSO Eskil Elmer, M.D., Ph.D. and neuroscientist Magnus Hansson, M.D., Ph.D., and colleagues have for the first time ever demonstrated the mitochondrial permeability transition (mPT) or "megapore" occurs in viable adult human neuron mitochondria and the ability of cyclosporin-A to block its formation.

18 Nov 2008

Ginkgo's benefits for cognitive decline treatment supported by scientific research

A vast body of research supports numerous health benefits for ginkgo extracts, particularly for treating various symptoms and conditions associated with declining cognitive performance and poor circulation, says the American Botanical Council, an independent nonprofit research and education organization.

18 Nov 2008

Fitch Ratings revises Merck & Co.'s outlook

Fitch Ratings has affirmed Merck & Co.'s (Merck) ratings, and revised the Rating Outlook to Negative from Stable.

18 Nov 2008

Celprogen introduces in vivo model for human glioblastoma

Celprogen Inc. has announced that they have successfully validated an in vivo model system for testing efficacy of cancer drugs and also novel drug candidates for Human Glioblastoma.

18 Nov 2008

Altus Pharmaceuticals reaffirms plan to submit NDA for Trizytek

Altus Pharmaceuticals Inc. announced today that it is reaffirming its plan to submit a new drug application (NDA) for Trizytek TM (liprotamase) in the first-half of 2009.

18 Nov 2008

Researchers reduce production of alpha-synuclein in the brain - offers hope for Parkinson's disease

Mayo Clinic researchers have developed a method to reduce the production of alpha-synuclein in the brain.

17 Nov 2008

Expectations drive patient preferences for treatment of spine problems

For patients with low back pain caused by a herniated disk, expectations of good results without surgery are the main factor affecting the preference for nonsurgical treatment, reports a study in the November 15 issue of Spine.

17 Nov 2008

New and improved scientific method to forecast the demand for key anti-malarial treatments

Treating infectious diseases while meeting escalating costs to do so continues to pose worldwide challenges, with one of the main issues being the ability to provide an adequate supply of drugs to treat infectious diseases.

17 Nov 2008

Innocoll receives fast track designation for Gentamicin surgical implant

Innocoll, Inc., a privately-held biopharmaceutical company, announced that the FDA has designated Gentamicin surgical implant as a Fast Track development program.

17 Nov 2008

Scientists find intra cellular pathway driving a deadly sub-type of breast cancer

An intra cellular pathway not previously linked to breast cancer is driving a sub-type of the disease that is highly lethal and disproportionately over-represented in African American women.

16 Nov 2008

Vigabatrin offers hope for treating relapse to methamphetamine abuse

A new study at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory suggests that vigabatrin (a.k.a. gamma vinyl-GABA, or GVG) blocks drug-seeking behavior in animals previously trained to associate methamphetamine with a particular environment.

16 Nov 2008

Hope for treating relapse to methamphetamine abuse

"Reinstatement of drug-seeking behavior after an extended period of abstinence is the number-one cause of drug-addiction relapse," said Brookhaven neuroanatomist Stephen Dewey, who led the research team. "This animal study suggests that vigabatrin could potentially prevent human methamphetamine addicts from relapsing."

13 Nov 2008

Phosphagenics' diclofenac enters trial phase in humans

Phosphagenics Limited ("Phosphagenics") announced today that it has initiated a phase 1 human clinical trial using its patented drug delivery system, TPM, for the targeted delivery of a leading non steroidal anti-inflammatory drug (NSAID), diclofenac.

12 Nov 2008